In a move that could put pressure on HIV/AIDS drugmakers to ease control of their patented products, yesterday the French-backed health fund UNITAID said that its executive board has made a landmark decision to establish a Patent Pool for AIDS medicines. The organization's founder members include the UK, Chile, Brazil, Norway and France.
The pool, scheduled to start operating in mid-2010, aims to make newer medicines available in patient-adapted form, at lower prices, for low- and middle-income countries. UNITAID has committed to provide start-up funds of up to $4 million over the next year. Expected savings exceed $1billion a year, which will make more medicines available for more people.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze